Rallybio (RLYB) Competitors $0.54 +0.00 (+0.19%) Closing price 04:00 PM EasternExtended Trading$0.54 +0.00 (+0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLYB vs. ADAG, CRDL, PLRX, EQ, HOWL, CLNN, LITS, ENTX, IMUX, and ASRTShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Adagene (ADAG), Cardiol Therapeutics (CRDL), Pliant Therapeutics (PLRX), Equillium (EQ), Werewolf Therapeutics (HOWL), Clene (CLNN), Lite Strategy (LITS), Entera Bio (ENTX), Immunic (IMUX), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. Its Competitors Adagene Cardiol Therapeutics Pliant Therapeutics Equillium Werewolf Therapeutics Clene Lite Strategy Entera Bio Immunic Assertio Adagene (NASDAQ:ADAG) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability. Is ADAG or RLYB more profitable? Adagene has a net margin of 0.00% compared to Rallybio's net margin of -5,473.33%. Adagene's return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Rallybio -5,473.33%-71.66%-65.06% Which has higher valuation and earnings, ADAG or RLYB? Adagene has higher earnings, but lower revenue than Rallybio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K843.63-$33.42MN/AN/ARallybio$761K29.42-$57.78M-$0.94-0.57 Which has more risk & volatility, ADAG or RLYB? Adagene has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.1, suggesting that its stock price is 210% less volatile than the S&P 500. Does the media prefer ADAG or RLYB? In the previous week, Rallybio had 3 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Rallybio and 1 mentions for Adagene. Adagene's average media sentiment score of 0.83 beat Rallybio's score of 0.39 indicating that Adagene is being referred to more favorably in the media. Company Overall Sentiment Adagene Positive Rallybio Neutral Do institutionals and insiders have more ownership in ADAG or RLYB? 9.5% of Adagene shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 8.7% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ADAG or RLYB? Adagene presently has a consensus target price of $7.00, suggesting a potential upside of 291.06%. Rallybio has a consensus target price of $5.00, suggesting a potential upside of 833.18%. Given Rallybio's higher possible upside, analysts clearly believe Rallybio is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Rallybio 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 SummaryAdagene beats Rallybio on 11 of the 15 factors compared between the two stocks. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.39M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-0.5722.9285.4427.36Price / Sales29.42270.00515.26195.91Price / CashN/A46.9537.5761.53Price / Book0.3610.5512.426.82Net Income-$57.78M-$52.58M$3.32B$276.89M7 Day Performance-6.93%1.09%1.01%0.27%1 Month Performance-9.71%16.09%10.75%8.31%1 Year Performance-50.84%18.41%76.20%35.60% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio3.0318 of 5 stars$0.54+0.2%$5.00+833.2%-50.5%$22.35M$640K-0.5740Analyst DowngradeADAGAdagene2.5261 of 5 stars$1.96-1.5%$7.00+257.1%-16.7%$92.38M$100K0.00260CRDLCardiol Therapeutics3.1082 of 5 stars$1.07-1.4%$8.00+651.2%-43.5%$91.53MN/A-3.1320News CoveragePLRXPliant Therapeutics4.0873 of 5 stars$1.48-1.0%$8.19+455.1%-89.0%$90.55M$1.58M-0.4390EQEquillium0.803 of 5 stars$1.52+1.0%$1.00-34.0%+42.4%$90.15M$16.55M-2.7140Gap UpHOWLWerewolf Therapeutics3.4663 of 5 stars$1.95-4.2%$8.00+311.3%-14.8%$88.95M$1.88M-1.1940News CoverageGap UpCLNNClene3.0801 of 5 stars$8.74-15.7%$32.60+273.2%+49.4%$88.36M$340K-2.33100News CoverageNegative NewsAnalyst ForecastHigh Trading VolumeLITSLite StrategyN/A$2.45-5.8%N/AN/A$87.34M$65.30M-0.52100ENTXEntera Bio2.0666 of 5 stars$1.90+3.3%$10.00+426.3%+41.9%$86.76M$166K-7.3120IMUXImmunic2.2225 of 5 stars$0.88-6.5%$9.50+980.8%-41.9%$86.71MN/A-0.9470ASRTAssertio2.8777 of 5 stars$0.88-1.9%$2.38+170.8%-23.0%$84.40M$117.10M-1.9520Analyst Upgrade Related Companies and Tools Related Companies Adagene Alternatives Cardiol Therapeutics Alternatives Pliant Therapeutics Alternatives Equillium Alternatives Werewolf Therapeutics Alternatives Clene Alternatives Lite Strategy Alternatives Entera Bio Alternatives Immunic Alternatives Assertio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLYB) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
